- Home
- TYRA vs NVRI Comparison
TYRA vs NVRI Comparison
Compare TYRA & NVRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYRA
- NVRI
- Stock Information
- Founded
- TYRA 2018
- NVRI 1853
- Country
- TYRA United States
- NVRI United States
- Employees
- TYRA N/A
- NVRI N/A
- Industry
- TYRA Biotechnology: Pharmaceutical Preparations
- NVRI Diversified Commercial Services
- Sector
- TYRA Health Care
- NVRI Miscellaneous
- Exchange
- TYRA Nasdaq
- NVRI Nasdaq
- Market Cap
- TYRA 556.4M
- NVRI 521.3M
- IPO Year
- TYRA 2021
- NVRI N/A
- Fundamental
- Price
- TYRA $10.09
- NVRI $7.05
- Analyst Decision
- TYRA Strong Buy
- NVRI Hold
- Analyst Count
- TYRA 6
- NVRI 1
- Target Price
- TYRA $30.50
- NVRI $10.00
- AVG Volume (30 Days)
- TYRA 281.8K
- NVRI 694.1K
- Earning Date
- TYRA 05-08-2025
- NVRI 05-01-2025
- Dividend Yield
- TYRA N/A
- NVRI N/A
- EPS Growth
- TYRA N/A
- NVRI N/A
- EPS
- TYRA N/A
- NVRI N/A
- Revenue
- TYRA N/A
- NVRI $2,290,612,000.00
- Revenue This Year
- TYRA N/A
- NVRI N/A
- Revenue Next Year
- TYRA N/A
- NVRI $3.63
- P/E Ratio
- TYRA N/A
- NVRI N/A
- Revenue Growth
- TYRA N/A
- NVRI N/A
- 52 Week Low
- TYRA $6.42
- NVRI $4.72
- 52 Week High
- TYRA $29.60
- NVRI $12.79
- Technical
- Relative Strength Index (RSI)
- TYRA 52.97
- NVRI 60.92
- Support Level
- TYRA $8.80
- NVRI $6.67
- Resistance Level
- TYRA $10.56
- NVRI $7.36
- Average True Range (ATR)
- TYRA 0.75
- NVRI 0.35
- MACD
- TYRA 0.06
- NVRI 0.09
- Stochastic Oscillator
- TYRA 58.90
- NVRI 75.82
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
About NVRI Enviri Corporation
Enviri Corp is a market-leading, provider of environmental solutions for industrial and specialty waste streams, and equipment and technology for the rail sector. The company's current operations consist of three divisions: Harsco Environmental, Harsco Rail, and Clean Earth. The company gains its revenue from Harsco Environmental segment. Geographically company operates in USA and International Countries, with majority revenue from USA.